Douglas Floccare, | |
22 S Green Street, Baltimore, MD 21273-0001 | |
(240) 631-8101 | |
Not Available |
Full Name | Douglas Floccare |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 22 S Green Street, Baltimore, Maryland |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1215047972 | NPI | - | NPPES |
H254 | Other | MD | MEDICARE GROUP NUMBER |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207P00000X | Emergency Medicine | D0035291 (Maryland) | Primary |
Mailing Address | Practice Location Address |
---|---|
Douglas Floccare, Po Box 73276, Baltimore, MD 21273-0001 Ph: (301) 631-8101 | Douglas Floccare, 22 S Green Street, Baltimore, MD 21273-0001 Ph: (240) 631-8101 |
News Archive
Scientists have developed a new version of a medication, first isolated from the saliva of sea snails, that could be taken in pill form to relieve the most severe forms of pain as effectively as morphine but without risking addiction. An article on the topic appears in the current issue of Chemical & Engineering News, ACS' weekly newsmagazine.
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the first pivotal Phase III trial with pimavanserin in patients with Parkinson's disease psychosis, or PDP. The study did not meet its primary endpoint of antipsychotic efficacy as measured using the Scale for the Assessment of Positive Symptoms, or SAPS.
Georgia State University faculty have received a five-year, $3 million federal grant to further develop a tool that will allow researchers around the world to participate in extensive brain imaging analysis without sharing protected patient data.
Paratek Pharmaceuticals, Inc. has announced the dosing of the first patient in its Phase 3 clinical study of its lead drug candidate, omadacycline, for the treatment of Community Acquired Bacterial Pneumonia (CABP). This global Phase 3 study will assess the efficacy and safety of omadacycline compared with moxifloxacin in subjects with CABP.
› Verified 1 days ago
Ankita Taneja, MD, MPH Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 22 S Greene St, Baltimore, MD 21201 Phone: 410-328-2079 | |
Scott Mcpherson, M.D Emergency Medicine Medicare: Medicare Enrolled Practice Location: 301 Saint Paul Pl, Baltimore, MD 21202 Phone: 410-332-9809 | |
Larry Weiss, M.D Emergency Medicine Medicare: Medicare Enrolled Practice Location: 22 S Greene St, Baltimore, MD 21201 Phone: 410-328-4383 | |
Shannon Brandy Putman, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 600 N Wolfe St, Baltimore, MD 21287 Phone: 410-955-2280 | |
Arjun S Chanmugam, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 600 N Wolfe St, Baltimore, MD 21287 Phone: 410-955-2280 | |
Dr. Donald W Alves, MD, MS, FACEP Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1201 Reisterstown Road, Medical Services, Baltimore, MD 21208 Phone: 410-653-8366 Fax: 410-653-4290 | |
Michael Rayner Leedom, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 22 S Greene St, Emergency Dept, Baltimore, MD 21201 Phone: 410-328-8025 Fax: 410-328-8028 |